Medical Journal of Cairo University [The]. 2003; 71 (1): 147-57
em Inglês
| IMEMR
| ID: emr-63604
ABSTRACT
This study was done at NEMROCK and other private as well as official governmental oncology centers, where 30 patients with residual or relapsed high grade gliomas received temozolomide at a dose of 200 mg/m2/day for five successive days to be recycled on day 21 for a total of six courses. Drug administration was quite safe with accepted toxicity profiles. The response parameters, including partial response, stationary disease and progressive neoplastic process, were documented in 33%, 45% and 22%, respectively
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Recidiva
/
Astrocitoma
/
Tomógrafos Computadorizados
/
Resultado do Tratamento
/
Glioblastoma
/
Antineoplásicos Alquilantes
/
Gerenciamento Clínico
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Med. J. Cairo Univ.
Ano de publicação:
2003
Similares
MEDLINE
...
LILACS
LIS